Hemispherx Biopharma (HEB) 0.32 $HEB
Hemispherx' Drug Ampligen Plus Intranasal Seasonal Influenza Vaccine Induces Cross-Reactive Antibody Formation Against Avian H5N1 and H7N9 Influenza HA in Humans
GlobeNewswire - Mon Sep 15, 7:30AM CDT
Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"
, announced today a peer-reviewed publication entitled "Intranasal Seasonal Influenza Vaccine and a TLR-3 Agonist, Rintatolimod, Induced Cross-Reactive IgA Antibody Formation Against Avian H5N1 and H7N9 Influenza HA in Humans" (Vaccine (2014), http://dx.doi.org/10.1016/j.vaccine.2014.07.078). The authors of the publication include staff of Hemispherx.
Ebola-Stricken Doc Receives Experimental Drug, But Which One?
at The Street - Thu Sep 11, 1:20PM CDT
Twitter abuzz with speculation that Tekmira's experimental Ebola therapy is being used to treat patient.
Trade Ebola Stocks? Sure, But Don't Bet on Big Business Opportunity
at The Street - Wed Sep 10, 8:36AM CDT
The Ebola outbreak in West Africa is a public health emergency which has also captured the attention of U.S. investors (perhaps I should say traders.)
Hot Stock: Hemispherx Biopharma, Shares Gain 25.1% (HEB)
Comtex SmarTrend(R) - Mon Sep 08, 10:08AM CDT
Hemispherx Biopharma (AMEX:HEB) is one of today's best performing penny stocks, up 25.1% to $0.35 on 18.4x average daily volume. Thus far today, Hemispherx Biopharma has traded 7.0 million shares, vs. average volume of 378,000 shares per day. The stock has outperformed the Dow (25.1% to the Dow's -0.1%) and outperformed the S&P 500 (25.1% to the S&P's -0.2%) during today's trading.
Hemispherx Biopharma and United States Army Medical Research Institute of Infectious Diseases (USAMRIID) Agree to Collaborate in Studying Alferon(R) and Ampligen(R) Against the Ebola Virus
GlobeNewswire - Mon Sep 08, 7:30AM CDT
Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx" , announced that the Company and USAMRIID scientists have agreed to test Alferon(R), the only multi-species, natural alpha interferon (IFN) commercially approved in the U.S. and Ampligen(R), an experimental drug, to be evaluated against the deadly Ebola virus, which has been and remains a major focus of efforts at USAMRIID, a unit of the Department of Defense responsible for medical biological defense research.
Hemispherx Biopharma to Present at the 16th Annual Rodman & Renshaw Global Investment Conference in New York City September 8-10th
GlobeNewswire - Wed Sep 03, 7:30AM CDT
Hemispherx Biopharma (NYSE MKT:HEB) today announced it will be featured as a presenting company at the 16 Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held September 8-10, 2014, at the New York Palace Hotel in New York City. Updates on the Company's Alferon(R) N manufacturing expansion program and the Ampligen(R) (an experimental therapeutic) Chronic Fatigue Syndrome (CFS) program will be provided.
Market Movers - Biotech Stocks -- Progenics Pharma, Rexahn Pharma, ImmunoGen, Hemispherx Biopharma, and Incyte
PR Newswire - Thu Aug 21, 8:20AM CDT
On Wednesday, August 20, 2014, the NASDAQ Composite ended at 4,526.48, down 0.02%, the Dow Jones Industrial Average finished the day 0.35% higher at 16,979.13, and the S&P 500 closed at 1,986.51, up 0.25%. The gains were broad based as eight out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 726.51, up 0.01%, and the index has advanced 2.23% in the last one month. Investor-Edge has initiated coverage on the following equities: Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), Rexahn Pharmaceuticals Inc. (NYSE MKT: RNN), ImmunoGen Inc. (NASDAQ: IMGN), Hemispherx Biopharma Inc. (NYSE MKT: HEB), and Incyte Corporation (NASDAQ: INCY). Free research on these five companies can be accessed at:
Sarepta Should Shut Up About Ebola, Focus on Job No. 1
at The Street - Wed Aug 06, 11:07AM CDT
By publicizing its outreach to the U.S. government about an experimental ebola treatment, Sarepta comes off looking like just another opportunistic, self-promoting drug developer.
Traders Get Bullish on Shares of Hemispherx Biopharma, Shares Up 5.3% (HEB)
Comtex SmarTrend(R) - Mon Aug 04, 10:10AM CDT
Hemispherx Biopharma (AMEX:HEB) is one of today's best performing penny stocks, up 5.3% to $0.30 on 1.0x average daily volume. Hemispherx Biopharma has traded 597,000 shares thus far today, vs. average volume of 592,000 shares per day. The stock has outperformed the Dow (5.3% to the Dow's -0.3%) and outperformed the S&P 500 (5.3% to the S&P's -0.2%) during today's trading.
Hemispherx's Two Drugs, Ampligen(R) and Alferon(R) Ranked Highly in Sensitivity Testing Against MERS/SARS Coronaviruses
GlobeNewswire - Mon Aug 04, 7:30AM CDT
Hemispherx Biopharma (NYSE MKT:HEB) announced today a peer-reviewed electronic publication entitled "Sensitivity of SARS/MERS CoV to Interferons and Other Drugs Based on Achievable Serum Concentrations in Humans" in the current issue of Infectious Disorders - Drug Targets, vol. 14, 2014. The authors of the publication include D.R. Strayer and W.A. Carter, who are affiliated with Hemispherx.
Stock to Watch: Hemispherx Biopharma Up 8.0% (HEB)
Comtex SmarTrend(R) - Tue Jul 22, 10:09AM CDT
Hemispherx Biopharma (AMEX:HEB) is one of today's best performing penny stocks, up 8.0% to $0.28 on 1.2x average daily volume. Hemispherx Biopharma has traded 831,000 shares thus far today, vs. average volume of 666,000 shares per day. The stock has outperformed the Dow (8.8% to the Dow's 0.4%) and outperformed the S&P 500 (8.8% to the S&P's 0.5%) during today's trading.
Hemispherx Achieves High Ranking in Sensitivity Testing Against MERS/SARS Coronaviruses Compared to Other Drugs
GlobeNewswire - Tue Jul 22, 7:31AM CDT
Hemispherx Biopharma (NYSE MKT:HEB) announced that a new publication abstract in Infectious Disorder Drug Targets (2014 Jul 13. [Epub ahead of print]) is available for review as described in PubMed on July 16, 2014, and proposes that the Middle East Respiratory Syndrome (MERS)/(Severe Acute Respiratory Syndrome) SARS coronaviruses (CoV) may be most effectively inhibited by interferons (IFNs) and an IFN inducer (http://www.ncbi.nlm.nih.gov/pubmed/?term=Sensitivity+of+SARS%2FMERS+CoV+to+Interferons+and+Other+Drugs+Based+on+Achievable+Serum+Concentrations+in+Humans). The article, entitled "Sensitivity of SARS/MERS CoV to Interferons and Other Drugs Based on Achievable Serum Concentrations in Humans", is authored by Hemispherx scientists. It is suggested that correcting a viral induced defect in immunity may be the first significant way to decrease MERS/SARS associated mortality.
Hemispherx Biopharma and Bioclones, a Leading South African Biotechnology Company, Join Forces on Novel Therapeutic Cancer Vaccine
GlobeNewswire - Mon Jul 14, 7:30AM CDT
Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx" , announced a strategic alliance to develop multiple projects with Bioclones (Pty) Ltd. ("Bioclones" , a leading South African biotechnology company.
Hemispherx Biopharma and Bioclones Join Forces in Effort to Eradicate HIV/AIDS Virus Based on Recent Clinical Insights of Wistar Institute, University of Pennsylvania
GlobeNewswire - Tue Jul 08, 8:23AM CDT
Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx" , announced execution of an agreement to seek South African government approval to initiate a study of Alferon(R) N, the only FDA approved natural interferon, in the suppression of HIV Type 1 replication and the reduction/elimination of functional cell-associated HIV DNA integration (latent HIV). The study is contemplated as part of a broad strategic alliance with Bioclones (Pty) Ltd. ("Bioclones" , a leading South African biotechnology company.
Hemispherx Biopharma to Present During the 2014 BIO International Convention June 26
GlobeNewswire - Wed Jun 25, 7:30AM CDT
Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx" , will present a corporate update on their Advanced Therapies for the Human Immune System at 9:45 a.m. Pacific Time on June 26, during the 2014 BIO International Convention at the San Diego Convention Center.
5 Stocks Poised for Breakouts
at The Street - Fri Jun 13, 12:22PM CDT
These stocks look ready to break out and trade higher from current levels.
Hemispherx Biopharma Down 9.2%, Shares Slide into the Red (HEB)
Comtex SmarTrend(R) - Mon Mar 24, 10:41AM CDT
Hemispherx Biopharma (AMEX:HEB) is one of today's worst performing penny stocks, down 9.2% to $0.42 on 3.3x average daily volume. Thus far today, Hemispherx Biopharma has traded 5.3 million shares, vs. average volume of 1.6 million shares per day. The stock has underperformed the Dow (-9.2% to the Dow's -0.3%) and underperformed the S&P 500 (-9.2% to the S&P's -0.7%) during today's trading.
Hemispherx Biopharma, Inc. Presented Clinical Interpretations on CFS Treatment at the 11th Biennial International Research and Clinical Conference
GlobeNewswire - Mon Mar 24, 7:33AM CDT
Hemispherx Biopharma, Inc. (NYSE MKT:HEB) participated in the 11th Biennial International Research and Clinical Conference held in San Francisco, California, USA, on March 20-23, 2014. The title of the presentation was "Differential Exercise Responses to Rintatolimod [Ampligen(R)] Exhibited by Patients with Severe Chronic Fatigue Syndrome (CFS)". This Phase III prospective, double-blind, randomized, placebo-controlled trial was conducted at twelve centers by leading researchers in fatigue and post-exertional fatigue.
Momentum Indicators for Health Care Equities -- Research on Arena Pharma, Hemispherx Biopharma, PDL BioPharma and Celgene
PR Newswire - Thu Mar 20, 7:16AM CDT
The trading session on Wednesday, March 19, 2014 ended on a negative note as the S&P 500 finished at 1,860.77, down 0.61%; the NASDAQ Composite closed at 4,307.60, down 0.59%; the Dow Jones Industrial Average finished the session 0.70% lower at 16,222.17. The losses were broad based as all the sectors ended the session in negative. The S&P 500 Health Care Sector Index finished the day at 686.44, down 0.37%, while the same has advanced 1.72% in the previous three trading sessions. Investor-Edge has initiated coverage on the following equities: Arena Pharmaceuticals Inc. (NASDAQ: ARNA), Hemispherx Biopharma Inc. (AMEX: HEB), PDL BioPharma Inc. (NASDAQ: PDLI) and Celgene Corp. (NASDAQ: CELG). Free technical research on ARNA, HEB, PDLI and CELG can be downloaded upon signing up at:
Hemispherx' Drug Ampligen Plus Intranasal Seasonal Influenza Vaccine Induces Cross-Reactive Antibody Formation Against Avian H5N1 and H7N9 Influenza HA in Humans
GlobeNewswire - Mon Sep 15, 7:30AM CDT
Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"
, announced today a peer-reviewed publication entitled "Intranasal Seasonal Influenza Vaccine and a TLR-3 Agonist, Rintatolimod, Induced Cross-Reactive IgA Antibody Formation Against Avian H5N1 and H7N9 Influenza HA in Humans" (Vaccine (2014), http://dx.doi.org/10.1016/j.vaccine.2014.07.078). The authors of the publication include staff of Hemispherx. Ebola-Stricken Doc Receives Experimental Drug, But Which One?
at The Street - Thu Sep 11, 1:20PM CDT
Twitter abuzz with speculation that Tekmira's experimental Ebola therapy is being used to treat patient.
Trade Ebola Stocks? Sure, But Don't Bet on Big Business Opportunity
at The Street - Wed Sep 10, 8:36AM CDT
The Ebola outbreak in West Africa is a public health emergency which has also captured the attention of U.S. investors (perhaps I should say traders.)
Hot Stock: Hemispherx Biopharma, Shares Gain 25.1% (HEB)
Comtex SmarTrend(R) - Mon Sep 08, 10:08AM CDT
Hemispherx Biopharma (AMEX:HEB) is one of today's best performing penny stocks, up 25.1% to $0.35 on 18.4x average daily volume. Thus far today, Hemispherx Biopharma has traded 7.0 million shares, vs. average volume of 378,000 shares per day. The stock has outperformed the Dow (25.1% to the Dow's -0.1%) and outperformed the S&P 500 (25.1% to the S&P's -0.2%) during today's trading.
Hemispherx Biopharma and United States Army Medical Research Institute of Infectious Diseases (USAMRIID) Agree to Collaborate in Studying Alferon(R) and Ampligen(R) Against the Ebola Virus
GlobeNewswire - Mon Sep 08, 7:30AM CDT
Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"
, announced that the Company and USAMRIID scientists have agreed to test Alferon(R), the only multi-species, natural alpha interferon (IFN) commercially approved in the U.S. and Ampligen(R), an experimental drug, to be evaluated against the deadly Ebola virus, which has been and remains a major focus of efforts at USAMRIID, a unit of the Department of Defense responsible for medical biological defense research. Hemispherx Biopharma to Present at the 16th Annual Rodman & Renshaw Global Investment Conference in New York City September 8-10th
GlobeNewswire - Wed Sep 03, 7:30AM CDT
Hemispherx Biopharma (NYSE MKT:HEB) today announced it will be featured as a presenting company at the 16 Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held September 8-10, 2014, at the New York Palace Hotel in New York City. Updates on the Company's Alferon(R) N manufacturing expansion program and the Ampligen(R) (an experimental therapeutic) Chronic Fatigue Syndrome (CFS) program will be provided.
Market Movers - Biotech Stocks -- Progenics Pharma, Rexahn Pharma, ImmunoGen, Hemispherx Biopharma, and Incyte
PR Newswire - Thu Aug 21, 8:20AM CDT
On Wednesday, August 20, 2014, the NASDAQ Composite ended at 4,526.48, down 0.02%, the Dow Jones Industrial Average finished the day 0.35% higher at 16,979.13, and the S&P 500 closed at 1,986.51, up 0.25%. The gains were broad based as eight out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 726.51, up 0.01%, and the index has advanced 2.23% in the last one month. Investor-Edge has initiated coverage on the following equities: Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), Rexahn Pharmaceuticals Inc. (NYSE MKT: RNN), ImmunoGen Inc. (NASDAQ: IMGN), Hemispherx Biopharma Inc. (NYSE MKT: HEB), and Incyte Corporation (NASDAQ: INCY). Free research on these five companies can be accessed at:
Sarepta Should Shut Up About Ebola, Focus on Job No. 1
at The Street - Wed Aug 06, 11:07AM CDT
By publicizing its outreach to the U.S. government about an experimental ebola treatment, Sarepta comes off looking like just another opportunistic, self-promoting drug developer.
Traders Get Bullish on Shares of Hemispherx Biopharma, Shares Up 5.3% (HEB)
Comtex SmarTrend(R) - Mon Aug 04, 10:10AM CDT
Hemispherx Biopharma (AMEX:HEB) is one of today's best performing penny stocks, up 5.3% to $0.30 on 1.0x average daily volume. Hemispherx Biopharma has traded 597,000 shares thus far today, vs. average volume of 592,000 shares per day. The stock has outperformed the Dow (5.3% to the Dow's -0.3%) and outperformed the S&P 500 (5.3% to the S&P's -0.2%) during today's trading.
Hemispherx's Two Drugs, Ampligen(R) and Alferon(R) Ranked Highly in Sensitivity Testing Against MERS/SARS Coronaviruses
GlobeNewswire - Mon Aug 04, 7:30AM CDT
Hemispherx Biopharma (NYSE MKT:HEB) announced today a peer-reviewed electronic publication entitled "Sensitivity of SARS/MERS CoV to Interferons and Other Drugs Based on Achievable Serum Concentrations in Humans" in the current issue of Infectious Disorders - Drug Targets, vol. 14, 2014. The authors of the publication include D.R. Strayer and W.A. Carter, who are affiliated with Hemispherx.
Stock to Watch: Hemispherx Biopharma Up 8.0% (HEB)
Comtex SmarTrend(R) - Tue Jul 22, 10:09AM CDT
Hemispherx Biopharma (AMEX:HEB) is one of today's best performing penny stocks, up 8.0% to $0.28 on 1.2x average daily volume. Hemispherx Biopharma has traded 831,000 shares thus far today, vs. average volume of 666,000 shares per day. The stock has outperformed the Dow (8.8% to the Dow's 0.4%) and outperformed the S&P 500 (8.8% to the S&P's 0.5%) during today's trading.
Hemispherx Achieves High Ranking in Sensitivity Testing Against MERS/SARS Coronaviruses Compared to Other Drugs
GlobeNewswire - Tue Jul 22, 7:31AM CDT
Hemispherx Biopharma (NYSE MKT:HEB) announced that a new publication abstract in Infectious Disorder Drug Targets (2014 Jul 13. [Epub ahead of print]) is available for review as described in PubMed on July 16, 2014, and proposes that the Middle East Respiratory Syndrome (MERS)/(Severe Acute Respiratory Syndrome) SARS coronaviruses (CoV) may be most effectively inhibited by interferons (IFNs) and an IFN inducer (http://www.ncbi.nlm.nih.gov/pubmed/?term=Sensitivity+of+SARS%2FMERS+CoV+to+Interferons+and+Other+Drugs+Based+on+Achievable+Serum+Concentrations+in+Humans). The article, entitled "Sensitivity of SARS/MERS CoV to Interferons and Other Drugs Based on Achievable Serum Concentrations in Humans", is authored by Hemispherx scientists. It is suggested that correcting a viral induced defect in immunity may be the first significant way to decrease MERS/SARS associated mortality.
Hemispherx Biopharma and Bioclones, a Leading South African Biotechnology Company, Join Forces on Novel Therapeutic Cancer Vaccine
GlobeNewswire - Mon Jul 14, 7:30AM CDT
Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"
, announced a strategic alliance to develop multiple projects with Bioclones (Pty) Ltd. ("Bioclones" , a leading South African biotechnology company. Hemispherx Biopharma and Bioclones Join Forces in Effort to Eradicate HIV/AIDS Virus Based on Recent Clinical Insights of Wistar Institute, University of Pennsylvania
GlobeNewswire - Tue Jul 08, 8:23AM CDT
Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"
, announced execution of an agreement to seek South African government approval to initiate a study of Alferon(R) N, the only FDA approved natural interferon, in the suppression of HIV Type 1 replication and the reduction/elimination of functional cell-associated HIV DNA integration (latent HIV). The study is contemplated as part of a broad strategic alliance with Bioclones (Pty) Ltd. ("Bioclones" , a leading South African biotechnology company. Hemispherx Biopharma to Present During the 2014 BIO International Convention June 26
GlobeNewswire - Wed Jun 25, 7:30AM CDT
Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"
, will present a corporate update on their Advanced Therapies for the Human Immune System at 9:45 a.m. Pacific Time on June 26, during the 2014 BIO International Convention at the San Diego Convention Center. 5 Stocks Poised for Breakouts
at The Street - Fri Jun 13, 12:22PM CDT
These stocks look ready to break out and trade higher from current levels.
Hemispherx Biopharma Down 9.2%, Shares Slide into the Red (HEB)
Comtex SmarTrend(R) - Mon Mar 24, 10:41AM CDT
Hemispherx Biopharma (AMEX:HEB) is one of today's worst performing penny stocks, down 9.2% to $0.42 on 3.3x average daily volume. Thus far today, Hemispherx Biopharma has traded 5.3 million shares, vs. average volume of 1.6 million shares per day. The stock has underperformed the Dow (-9.2% to the Dow's -0.3%) and underperformed the S&P 500 (-9.2% to the S&P's -0.7%) during today's trading.
Hemispherx Biopharma, Inc. Presented Clinical Interpretations on CFS Treatment at the 11th Biennial International Research and Clinical Conference
GlobeNewswire - Mon Mar 24, 7:33AM CDT
Hemispherx Biopharma, Inc. (NYSE MKT:HEB) participated in the 11th Biennial International Research and Clinical Conference held in San Francisco, California, USA, on March 20-23, 2014. The title of the presentation was "Differential Exercise Responses to Rintatolimod [Ampligen(R)] Exhibited by Patients with Severe Chronic Fatigue Syndrome (CFS)". This Phase III prospective, double-blind, randomized, placebo-controlled trial was conducted at twelve centers by leading researchers in fatigue and post-exertional fatigue.
Momentum Indicators for Health Care Equities -- Research on Arena Pharma, Hemispherx Biopharma, PDL BioPharma and Celgene
PR Newswire - Thu Mar 20, 7:16AM CDT
The trading session on Wednesday, March 19, 2014 ended on a negative note as the S&P 500 finished at 1,860.77, down 0.61%; the NASDAQ Composite closed at 4,307.60, down 0.59%; the Dow Jones Industrial Average finished the session 0.70% lower at 16,222.17. The losses were broad based as all the sectors ended the session in negative. The S&P 500 Health Care Sector Index finished the day at 686.44, down 0.37%, while the same has advanced 1.72% in the previous three trading sessions. Investor-Edge has initiated coverage on the following equities: Arena Pharmaceuticals Inc. (NASDAQ: ARNA), Hemispherx Biopharma Inc. (AMEX: HEB), PDL BioPharma Inc. (NASDAQ: PDLI) and Celgene Corp. (NASDAQ: CELG). Free technical research on ARNA, HEB, PDLI and CELG can be downloaded upon signing up at:
